Gland Pharma growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+14.5%−0.9%+56.3%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+28.4%−4.8%+30.1%
+35.3%−9.9%+12.6%
+47.1%−9.6%−1.1%
+47.1%−9.6%−1.1%
+11.5%+5.3%+21.5%
+13.2%+4.9%+9.6%
+12.8%−8.2%+173.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GLAND₹3,074.50

Gland Pharma Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABAUROPHARMAPPLPHARMASYNGENEWOCKPHARMAASTERDMCOHANCELALPATHLABMcap ₹50,655 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+56.3-0.9+14.5—
EBITDA Growth—+30.1-4.8+28.4—
EBIT Growth—+12.6-9.9+35.3—
Net Income Growth—-1.1-9.6+47.1—
EPS Growth—-1.1-9.6+47.1—
Total Assets Growth—+21.5+5.3+11.5—
Total Equity Growth—+9.6+4.9+13.2—
Cash from Operations Growth—+173.9-8.2+12.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.